King's College London
London, United Kingdom
NCT Number: NCT05032833
The study will evaluate safety, tolerability and PK profile of 5-MeO-DMT in healthy subjects
Looking for future studies?
Notify Me25 year–55 year
All sexes
Interventional
Phase 1
London, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A single dose of 5-MeO-DMT will be administered intranasally
A single dose of placebo will be administered intranasally
Time frame: From screening through to the follow up visit, up to 65 days
Time frame: Day 1 (dosing day) and Day 2
Time frame: Day 1 (dosing day) and Day 2
Time frame: Day 1 (dosing day) and Day 2
Beckley Psytech Limited
Industry
A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05347849
Pharmacokinetics in Healthy Adults
London, United Kingdom
View Trial DetailsNCT02561442
Pharmacokinetics in Healthy Adults
View Trial Details